Moncef Slaoui has a tough job ahead of him - restructuring GlaxoSmithKline's R&D organization in order to ensure the company's future. But will he succeed in keeping his team on top in these challenging times? Marie Shields investigates.
Accenture’s Health and Life Sciences Group takes a look at some winning strategies for a turning point in the pharmaceutical industry.
Pfizer’s Diane Jorkasky champions the use of geographically diverse clinical research units to transform the conduct of phase I trials. NGP found out why.
The key to the rapid adoption of new products, whether pharmaceuticals, biologics or medical devices, lies essentially in how closely these new products address medical needs.
How the efficiency and cost effectiveness of cardiac safety studies will be enhanced in the near future. By Tosja K. Zywietz, Director R&D at Cardinal Health Research Services Germany